Aidaluo® is the commercial brand name of Ebdarokimab Injection, a fully human monoclonal antibody developed by Akesobio. It targets the P2X3 receptor to inhibit pain signal transmission in sensory neurons.
Main Indications
For the treatment of refractory chronic cough in adult patients.
Clinical Research
Phase III studies showed that ebdarokimab significantly reduced 24-hour cough frequency compared with placebo. It demonstrated sustained antitussive efficacy and acceptable tolerability in patients with refractory chronic cough.
Common Side Effects
Dysgeusia, headache, fatigue, injection site reactions;
Other common reactions: nausea, dizziness. Rare serious adverse events include severe hypersensitivity reactions.
Approval Status in China
Original drug Aidaluo® (Ebdarokimab Injection) was officially approved for marketing in China in 2024, with the specification of 135mg (1mL) per vial. It is currently a prescription drug.
Buy Aidaluo (Ebdarokimab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
